169 related articles for article (PubMed ID: 36643629)
1. CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.
Jia D; Xiong L; Xue H; Li J
PeerJ; 2023; 11():e14668. PubMed ID: 36643629
[TBL] [Abstract][Full Text] [Related]
2. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
3. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
Xu Y; Li Q; Lin H
Cell Signal; 2024 Mar; 115():111012. PubMed ID: 38113979
[TBL] [Abstract][Full Text] [Related]
5. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
6. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
Liang HY; Chen SL; Cai SH; Zhang SW; Yang X; Wei LJ; Luo RZ; Liu LL
J Med Virol; 2023 Mar; 95(3):e28605. PubMed ID: 36815510
[TBL] [Abstract][Full Text] [Related]
7. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T; Yu H; Dai X; Zhang X
Front Immunol; 2022; 13():971428. PubMed ID: 35958549
[TBL] [Abstract][Full Text] [Related]
8. Expression and Clinical Significance of CMTM6 in Nonsmall Cell Lung Cancer.
Hou X; He S; Zhang D; Yang C; Shi Y; Zhang K
DNA Cell Biol; 2020 Oct; ():. PubMed ID: 33090010
[TBL] [Abstract][Full Text] [Related]
9. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Zhao Y; Zhang M; Pu H; Guo S; Zhang S; Wang Y
Front Oncol; 2020; 10():585961. PubMed ID: 33552963
[TBL] [Abstract][Full Text] [Related]
11. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
12. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
[TBL] [Abstract][Full Text] [Related]
13.
Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
[TBL] [Abstract][Full Text] [Related]
14. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract][Full Text] [Related]
15. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
Muranushi R; Araki K; Yokobori T; Chingunjav B; Hoshino K; Dolgormaa G; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Shimoda Y; Sano R; Oyama T; Saeki H; Shirabe K
Cancer Sci; 2021 Aug; 112(8):3314-3323. PubMed ID: 34080242
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
17. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM; Abuharfeil NM; Darmani H
Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
20. Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments
Meng H; Li S; Li Q; Wang Y; Wang G; Qu Y
Front Mol Neurosci; 2022; 15():1026927. PubMed ID: 36698778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
